NCT04690088 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Adams JP, Murphy PG
Obesity in anaesthesia and intensive care. Br J Anaesth. 2000 Jul;85(1):91-108. Review.
Cheymol G
Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000 Sep;39(3):215-31. Review.
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report
National Institutes of Health. Obes Res. 1998 Sep;6 Suppl 2:51S-209S. Review. Erratum in: Obes Res 1998 Nov;6(6):464.
Egan TD, Kern SE, Muir KT, White J
Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers. Br J Anaesth. 2004 Mar;92(3):335-43.
Michelsen LG, Hug CC Jr
The pharmacokinetics of remifentanil. J Clin Anesth. 1996 Dec;8(8):679-82. Review.

Remifentanilio Titravimo būdų Palyginimas, Remiantis pacientų Budimo Kokybe Ligotai Nutukusiems Pacientams po laparoskopinių skrandžio tūrio mažinimo operacijų

Details for clinical trial NCT04690088

Clinical trial NCT04690088 - References